

Standard Control Formulary

January 2023 Updates

| Removals | Add-Backs |
|----------|-----------|
| 23 | 6 |

Removals

| Drug Class | Removed Product(s) | Formulary Options |
|--|--|---|
| Antiarrhythmics | MULTAQ, NEXTERONE | amiodarone |
| Anti-Inflammatory, Cryopyrin-Associated Periodic Syndromes (CAPS) | ARCALYST | ILARIS |
| Asthma, Severe | NUCALA LYOPHILIZED | DUPIXENT, FASENRA, NUCALA (except lyophilized powder), TEZSPIRE, XOLAIR |
| Asthma, Steroid Inhalants* | ARNUITY ELLIPTA, FLOVENT DISKUS, QVAR REDHALER | FLOVENT HFA, PULMICORT FLEXHALER |
| Cancer, Antimetabolites | ALIMTA** | pemetrexed |
| Cancer, Poly-ADP Ribose Polymerase (PARP) Inhibitors | RUBRACA | LYNPARZA, ZEJULA |
| Cancer, Renal Cell Carcinoma | SUTENT**, VOTRIENT | sunitinib, CABOMETYX, INLYTA, LENVIMA, NEXAVAR |
| Endocrine, Metabolic Modifiers | NITYR | ORFADIN |
| Hematologic, Hemophilia B* | BENEFIX, IXINITY, RIXUBIS | ALPROLIX, REBINYN |
| Hereditary Angioedema* | FIRAZYR** | icatibant, RUCONEST |
| Overactive Bladder, Incontinence Urinary Antispasmodics* | TOVIAZ** | darifenacin ext-rel, oxybutynin ext-rel, solifenacin, tolterodine, tolterodine ext-rel, trospium, trospium ext-rel, GEMTESA |
| Pain & Inflammation, Non-steroidal Anti-Inflammatory Drugs (NSAIDs)* | diclofenac capsule 25 mg | diclofenac sodium, ibuprofen, meloxicam tablet, naproxen (except naproxen CR or naproxen suspension) |
| | diclofenac solution 2% | diclofenac sodium, diclofenac sodium gel 1%, diclofenac sodium solution 1.5%, ibuprofen, meloxicam tablet, naproxen (except naproxen CR or naproxen suspension) |
| Pain, Opioid Analgesics* | NUCYNTA | hydromorphone, morphine, oxycodone |
| | NUCYNTA ER | fentanyl transdermal, hydrocodone ext-rel, hydromorphone ext-rel, methadone, morphine ext-rel, XTAMPZA ER |
| | SUBSYS | fentanyl transmucosal lozenge |
| Pulmonary Fibrosis Agents | ESBRIET | pirfenidone, OFEV |

| Drug Class | Removed Product(s) | Formulary Options |
|-----------------|--------------------|--|
| Sleep Disorders | EDLUAR | doxepin, eszopiclone, ramelteon, zolpidem, zolpidem ext-rel, BELSOMRA, DAYVIGO |

Add-Backs

| Drug Class | Product(s) Added |
|--|--------------------------|
| Autoimmune Agents* | ILUMYA |
| Cancer, Follicular Lymphoma Phosphatidylinositol-3-kinase (PI3K) Inhibitors* | ZYDELIG |
| Hematologic, Hemophilia B* | ALPROLIX |
| Hematologic, Thrombocytopenia Agents* | MULPLETA (non-preferred) |
| Migraine, Calcitonin Gene-Related Peptide Inhibitors (CGRP) Inhibitors* | AIMOVIG |
| Parkinson's Disease* | RYTARY |

New to Market Updates

| Drug Class | Product(s) Added to Coverage |
|---|------------------------------|
| Asthma, Severe * | TEZSPIRE |
| Atopic Dermatitis* | ADBRY, CIBINQO |
| Cancer, Rearranged During Transfection (RET) Inhibitors | GAVRETO, RETEVMO |
| Dermatology, Acne Products* | WINLEVI |
| Sleep Disorder, Hypnotics* | DAYVIGO |

Tier 1 Strategy Updates

| Tier 1 Brand Formulary Removals | Generic Products Added Back |
|---------------------------------|---------------------------------------|
| ASACOL HD | mesalamine delayed-rel tablet 800 mg |
| ADDERALL XR | amphetamine-dextroamphetamine ext-rel |
| CONCERTA | methylphenidate ext-rel |

*Class has existing formulary exclusions. **Multi-source brand product

This chart contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Health and/or its affiliates.

Removals, Add-Backs and Tier-1 Updates as of September 29, 2022. Information subject to change.